Abstract MS2-2: Genomics to personalize therapy of metastatic breast cancers

摘要: Genomic studies have shown that breast cancer includes large number of rare genomic segments. This led to the development precision medicine where sequencing could be used identify drivers in individuals, would treated accordingly. 10 20 molecular alterations are being investigated context biomarker-driven therapeutic trials. PIK3CA, AKT1, ERBB2, PTEN, BRCA1/2, ESR1 mutations, FGFR1, CCND1 amplifications, AR expression. Beyond question clinical utility detecting these variants, there several challenges is facing cancer. The first challenge will better define which individuals and how target them. recent failures prospective trials testing (SAFIR01, SHIVA) highlights need understand what defines a targetable alteration. These also pointed out alterations, rather than pathway. Also, it9s important role on multiple play resistance. As illustration, reports suggest PIK3CA mutations associated lower sensitivity dual Her2 inhibition neoadjuvant setting. second generate tests predict therapies pathways, like mTOR or CDK4 inhibitors. To this regards, gene expression looks particularly attractive since it allows quantifying pathway activation. third earlier resistance targeted therapies. circulating DNA as diagnostic tool useful for early diagnosis Clinical technology currently starting. Finally, one major integrate immunotherapeutics application field medicine. High mutational loads neoantigen efficacy immunotherapeutics. Further combination with should rationalized based genomics. Overall, while candidate biomarkers exist technologies available, failed deliver until now patients metastatic Nevertheless, ongoing randomized drugs according open door treatment decisions genomics patients. Citation Format: Andre F. Genomics personalize therapy cancers. [abstract]. In: Proceedings Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; Antonio, TX. Philadelphia (PA): AACR; Res 2016;76(4 Suppl):Abstract nr MS2-2.